Treatment of Vascular Soft Tissue Sarcomas With Razoxane, Vindesine, and Radiation
- Department of Radiooncology, Academic Teaching Hospital, Feldkirch (Austria)
- Department of Therapeutic Radiology and Oncology, Medical University Graz (Austria)
- Department of Radiooncology, Medical University Vienna (Austria)
- Department of Radiooncology, General Hospital, Wiener Neustadt (Austria)
- Department of Radiooncology, Medical University Hospital Innsbruck (Austria)
Purpose: In previous studies, razoxane and vindesine together with radiotherapy was proved to be effective in soft tissue sarcomas (STS). Because razoxane leads to a redifferentiation of pathological tumor blood vessels, it was of particular interest to study the influence of this drug combination in vascular soft tissue sarcomas. Methods and Materials: This open multicenter Phase II study was performed by the Austrian Society of Radiooncology. Among 13 evaluable patients (10 angiosarcomas and 3 hemangio-pericytomas), 9 had unresectable measurable disease, 3 showed microscopic residuals, and 1 had a resection with clear margins. They received a basic treatment with razoxane and vindesine supported by radiation therapy. Outcome measures were objective response rates, survival time, and the incidence of distant metastases. Results: In nine patients with measurable vascular soft tissue sarcomas (eight angiosarcomas and one hemangiopericytoma), 6 complete remissions, 2 partial remissions, and 1 minor remission were achieved, corresponding to a major response rate of 89%. A maintenance therapy with razoxane and vindesine of 1 year or longer led to a suppression of distant metastases. The median survival time from the start of the treatment is 23+ months (range, 3-120+) for 12 patients with macroscopic and microscopic residual disease. The progression-free survival at 6 months was 75%. The combined treatment was associated with a low general toxicity, but attention must be given to increased normal tissue reactions. Conclusions: This trimodal treatment leads to excellent response rates, and it suppresses distant metastases when given as maintenance therapy.
- OSTI ID:
- 21276789
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 74, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2008.06.1492; PII: S0360-3016(08)02505-4; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Anticipated Intraoperative Electron Beam Boost, External Beam Radiation Therapy, and Limb-Sparing Surgical Resection for Patients with Pediatric Soft-Tissue Sarcomas of the Extremity: A Multicentric Pooled Analysis of Long-Term Outcomes
Intensive combined modality therapy including low-dose TBI in high-risk Ewing's sarcoma patients